NEW YORK (GenomeWeb News) – Proxeon today said that it has joined a new research consortium focused on developing new proteomics technologies for understanding the human proteome and its role in disease.
The Odense, Denmark-based firm said that it is one of 12 partners in the consortium, Proteomics Specification in Time and Space (Prospects). The consortium, which is headed by Matthias Mann of the Max Planck Institute of Biochemistry, is co-funded by the European Commission with €12 million ($15.6 million) for five years within the Research Framework Programme 7.
Prospect’s specific focus will be on functional proteomics and mass spectrometry. The consortium was launched earlier this year, and all of the data produced through the collaboration will be made available to the scientific community through online public databases.
In addition to Proxeon and Max Planck, the other partners in the consortium are Thermo Fisher Scientific in Germany; the Swiss Federal Institute of Technology; the University of Cambridge and the University of Dundee in the UK; the University of Southern Denmark; the Center for Genomic Regulation in Spain; the Royal Institute of Technology in Sweden; and the Hebrew University in Israel.